Standard

Biotin-decorated anti-cancer nucleotide theranostic conjugate of human serum albumin : Where the seed meets the soil? / Popova, Tatyana V.; Khan, Hamda; Chubarov, Alexey S. и др.

в: Bioorganic and Medicinal Chemistry Letters, Том 28, № 3, 01.02.2018, стр. 260-264.

Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование

Harvard

Popova, TV, Khan, H, Chubarov, AS, Lisitskiy, VA, Antonova, NM, Akulov, AE, Shevelev, OB, Zavjalov, EL, Silnikov, VN, Ahmad, S & Godovikova, TS 2018, 'Biotin-decorated anti-cancer nucleotide theranostic conjugate of human serum albumin: Where the seed meets the soil?', Bioorganic and Medicinal Chemistry Letters, Том. 28, № 3, стр. 260-264. https://doi.org/10.1016/j.bmcl.2017.12.061

APA

Popova, T. V., Khan, H., Chubarov, A. S., Lisitskiy, V. A., Antonova, N. M., Akulov, A. E., Shevelev, O. B., Zavjalov, E. L., Silnikov, V. N., Ahmad, S., & Godovikova, T. S. (2018). Biotin-decorated anti-cancer nucleotide theranostic conjugate of human serum albumin: Where the seed meets the soil? Bioorganic and Medicinal Chemistry Letters, 28(3), 260-264. https://doi.org/10.1016/j.bmcl.2017.12.061

Vancouver

Popova TV, Khan H, Chubarov AS, Lisitskiy VA, Antonova NM, Akulov AE и др. Biotin-decorated anti-cancer nucleotide theranostic conjugate of human serum albumin: Where the seed meets the soil? Bioorganic and Medicinal Chemistry Letters. 2018 февр. 1;28(3):260-264. doi: 10.1016/j.bmcl.2017.12.061

Author

Popova, Tatyana V. ; Khan, Hamda ; Chubarov, Alexey S. и др. / Biotin-decorated anti-cancer nucleotide theranostic conjugate of human serum albumin : Where the seed meets the soil?. в: Bioorganic and Medicinal Chemistry Letters. 2018 ; Том 28, № 3. стр. 260-264.

BibTeX

@article{a10c3384ba20430083ec3147fe38fa1d,
title = "Biotin-decorated anti-cancer nucleotide theranostic conjugate of human serum albumin: Where the seed meets the soil?",
abstract = "Human serum albumin is playing an increasing role as a drug carrier in clinical settings. Biotin molecules are often used as suitable tags in targeted anti-tumor drug delivery systems. We report on the synthesis and properties of a new multimodal theranostic conjugate based on an anti-cancer fluorinated nucleotide conjugated with a biotinylated dual-labeled albumin. Interestingly, in vitro and in vivo study revealed stronger anti-tumor activity of the non-tagged theranostic conjugate than that of the biotin-tagged conjugate, which can be explained by decreased binding of the biotin-tagged conjugate to cellular receptors. Our study sheds light on the importance of site-specific albumin modification for the design of albumin-based drugs with desirable pharmaceutical properties.",
keywords = "Anti-tumor activity, Biotinylated albumin conjugate, Dual-labeled human serum albumin, Fluorescence-based molecular imaging, Trifluorothymidine theranostic conjugate, CELLS, PERMEABILITY, DRUG-DELIVERY, VERSATILE PLATFORM, BREAST-CANCER, NANOPARTICLES, FC-RECEPTOR, THERAPY, DEPENDENT MULTIVITAMIN TRANSPORTER, EXPRESSION, Biotin/chemistry, Theranostic Nanomedicine, Humans, Structure-Activity Relationship, Dose-Response Relationship, Drug, Neoplasms, Experimental/drug therapy, Molecular Structure, Cell Proliferation/drug effects, Mice, SCID, Antineoplastic Agents/chemical synthesis, Animals, Cell Line, Tumor, Mice, Serum Albumin, Human/chemistry, Nucleotides/chemical synthesis, Drug Screening Assays, Antitumor",
author = "Popova, {Tatyana V.} and Hamda Khan and Chubarov, {Alexey S.} and Lisitskiy, {Vladimir A.} and Antonova, {Natalya M.} and Akulov, {Andrey E.} and Shevelev, {Oleg B.} and Zavjalov, {Evgenii L.} and Silnikov, {Vladimir N.} and Saheem Ahmad and Godovikova, {Tatyana S.}",
note = "Publisher Copyright: {\textcopyright} 2017 Elsevier Ltd",
year = "2018",
month = feb,
day = "1",
doi = "10.1016/j.bmcl.2017.12.061",
language = "English",
volume = "28",
pages = "260--264",
journal = "Bioorganic and Medicinal Chemistry Letters",
issn = "0960-894X",
publisher = "Elsevier Ltd",
number = "3",

}

RIS

TY - JOUR

T1 - Biotin-decorated anti-cancer nucleotide theranostic conjugate of human serum albumin

T2 - Where the seed meets the soil?

AU - Popova, Tatyana V.

AU - Khan, Hamda

AU - Chubarov, Alexey S.

AU - Lisitskiy, Vladimir A.

AU - Antonova, Natalya M.

AU - Akulov, Andrey E.

AU - Shevelev, Oleg B.

AU - Zavjalov, Evgenii L.

AU - Silnikov, Vladimir N.

AU - Ahmad, Saheem

AU - Godovikova, Tatyana S.

N1 - Publisher Copyright: © 2017 Elsevier Ltd

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Human serum albumin is playing an increasing role as a drug carrier in clinical settings. Biotin molecules are often used as suitable tags in targeted anti-tumor drug delivery systems. We report on the synthesis and properties of a new multimodal theranostic conjugate based on an anti-cancer fluorinated nucleotide conjugated with a biotinylated dual-labeled albumin. Interestingly, in vitro and in vivo study revealed stronger anti-tumor activity of the non-tagged theranostic conjugate than that of the biotin-tagged conjugate, which can be explained by decreased binding of the biotin-tagged conjugate to cellular receptors. Our study sheds light on the importance of site-specific albumin modification for the design of albumin-based drugs with desirable pharmaceutical properties.

AB - Human serum albumin is playing an increasing role as a drug carrier in clinical settings. Biotin molecules are often used as suitable tags in targeted anti-tumor drug delivery systems. We report on the synthesis and properties of a new multimodal theranostic conjugate based on an anti-cancer fluorinated nucleotide conjugated with a biotinylated dual-labeled albumin. Interestingly, in vitro and in vivo study revealed stronger anti-tumor activity of the non-tagged theranostic conjugate than that of the biotin-tagged conjugate, which can be explained by decreased binding of the biotin-tagged conjugate to cellular receptors. Our study sheds light on the importance of site-specific albumin modification for the design of albumin-based drugs with desirable pharmaceutical properties.

KW - Anti-tumor activity

KW - Biotinylated albumin conjugate

KW - Dual-labeled human serum albumin

KW - Fluorescence-based molecular imaging

KW - Trifluorothymidine theranostic conjugate

KW - CELLS

KW - PERMEABILITY

KW - DRUG-DELIVERY

KW - VERSATILE PLATFORM

KW - BREAST-CANCER

KW - NANOPARTICLES

KW - FC-RECEPTOR

KW - THERAPY

KW - DEPENDENT MULTIVITAMIN TRANSPORTER

KW - EXPRESSION

KW - Biotin/chemistry

KW - Theranostic Nanomedicine

KW - Humans

KW - Structure-Activity Relationship

KW - Dose-Response Relationship, Drug

KW - Neoplasms, Experimental/drug therapy

KW - Molecular Structure

KW - Cell Proliferation/drug effects

KW - Mice, SCID

KW - Antineoplastic Agents/chemical synthesis

KW - Animals

KW - Cell Line, Tumor

KW - Mice

KW - Serum Albumin, Human/chemistry

KW - Nucleotides/chemical synthesis

KW - Drug Screening Assays, Antitumor

UR - http://www.scopus.com/inward/record.url?scp=85039789362&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2017.12.061

DO - 10.1016/j.bmcl.2017.12.061

M3 - Article

C2 - 29305188

AN - SCOPUS:85039789362

VL - 28

SP - 260

EP - 264

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

SN - 0960-894X

IS - 3

ER -

ID: 12080297